A Bagust1, S Beale. 1. York Health Economics Consortium, University of York, Heslington, UK. ab13@york.ac.uk
Abstract
BACKGROUND: Type 2 diabetes is characterized by insulin resistance and the progressive loss of islet beta-cell function. Although the former is already established at diagnosis and changes little thereafter, beta-cell function continues to decline, leading to secondary failure of anti-hyperglycaemic therapies. AIM: To develop a quantitative model of the process of beta-cell function decay over time, using trial data. DESIGN: Re-analysis of published data. METHODS: The results of the Belfast Diet Study were re-analysed. Assuming patients are diagnosed at different stages in the disease process, time displacement of data was used to obtain a bi-partite spline model describing loss of insulin secretion over a 6-year period. RESULTS: The model was developed combining two phases, in which a long slow gradual loss of beta-cell function leads to a crisis in metabolic regulation, precipitating a much more rapid decay phase. This paradigm was consistent with a previous non-linear model of beta-cell mass regulation. DISCUSSION: This model may have important implications for targeting appropriate therapy to patients in each phase: delaying or avoiding full clinical type 2 diabetes in the first phase; and preventing the development of diabetic complications in the second phase.
BACKGROUND:Type 2 diabetes is characterized by insulin resistance and the progressive loss of islet beta-cell function. Although the former is already established at diagnosis and changes little thereafter, beta-cell function continues to decline, leading to secondary failure of anti-hyperglycaemic therapies. AIM: To develop a quantitative model of the process of beta-cell function decay over time, using trial data. DESIGN: Re-analysis of published data. METHODS: The results of the Belfast Diet Study were re-analysed. Assuming patients are diagnosed at different stages in the disease process, time displacement of data was used to obtain a bi-partite spline model describing loss of insulin secretion over a 6-year period. RESULTS: The model was developed combining two phases, in which a long slow gradual loss of beta-cell function leads to a crisis in metabolic regulation, precipitating a much more rapid decay phase. This paradigm was consistent with a previous non-linear model of beta-cell mass regulation. DISCUSSION: This model may have important implications for targeting appropriate therapy to patients in each phase: delaying or avoiding full clinical type 2 diabetes in the first phase; and preventing the development of diabetic complications in the second phase.
Authors: Abu Saleh Md Moin; Sangeeta Dhawan; Megan Cory; Peter C Butler; Robert A Rizza; Alexandra E Butler Journal: J Clin Endocrinol Metab Date: 2016-07-29 Impact factor: 5.958
Authors: A Avogaro; M Federici; J Betteridge; R Bonadonna; I W Campbell; G H Schernthaner; B Staels; E Farinaro; G Crepaldi Journal: J Endocrinol Invest Date: 2011-11 Impact factor: 4.256
Authors: Janna K Duong; Willem de Winter; Steve Choy; Nele Plock; Himanshu Naik; Walter Krauwinkel; Sandra A G Visser; Katia M Verhamme; Miriam C Sturkenboom; B H Stricker; Meindert Danhof Journal: Br J Clin Pharmacol Date: 2016-11-17 Impact factor: 4.335